BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35140266)

  • 1. Correlation of age of onset and clinical severity in Niemann-Pick disease type C1 with lysosomal abnormalities and gene expression.
    Baxter LL; Watkins-Chow DE; Johnson NL; Farhat NY; Platt FM; Dale RK; Porter FD; Pavan WJ; Rodriguez-Gil JL
    Sci Rep; 2022 Feb; 12(1):2162. PubMed ID: 35140266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A somatic cell defect is associated with the onset of neurological symptoms in a lysosomal storage disease.
    Rodriguez-Gil JL; Larson DM; Wassif CA; Yanjanin NM; Anderson SM; Kirby MR; Trivedi NS; Porter FD; Pavan WJ
    Mol Genet Metab; 2013; 110(1-2):188-90. PubMed ID: 23850077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1.
    Cluzeau CV; Watkins-Chow DE; Fu R; Borate B; Yanjanin N; Dail MK; Davidson CD; Walkley SU; Ory DS; Wassif CA; Pavan WJ; Porter FD
    Hum Mol Genet; 2012 Aug; 21(16):3632-46. PubMed ID: 22619379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for
    Tseng WC; Loeb HE; Pei W; Tsai-Morris CH; Xu L; Cluzeau CV; Wassif CA; Feldman B; Burgess SM; Pavan WJ; Porter FD
    Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30135069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics.
    Rodriguez-Gil JL; Baxter LL; Watkins-Chow DE; Johnson NL; Davidson CD; Carlson SR; Incao AA; ; Wallom KL; Farhat NY; Platt FM; Dale RK; Porter FD; Pavan WJ
    Hum Mol Genet; 2021 Nov; 30(24):2456-2468. PubMed ID: 34296265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
    Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
    Agrawal N; Farhat NY; Sinaii N; Do AD; Xiao C; Berry-Kravis E; Bianconi S; Masvekar R; Bielekova B; Solomon B; Porter FD
    Genet Med; 2023 Mar; 25(3):100349. PubMed ID: 36470574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sterol O-Acyltransferase 1 (
    Farhat NY; Alexander D; McKee K; Iben J; Rodriguez-Gil JL; Wassif CA; Cawley NX; Balch WE; Porter FD
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical Characterization of Methyl-β-Cyclodextrin for Pharmacological Activity to Reduce Lysosomal Cholesterol Accumulation in Niemann-Pick Disease Type C1 Cells.
    Li R; Hao J; Fujiwara H; Xu M; Yang S; Dai S; Long Y; Swaroop M; Li C; Vu M; Marugan JJ; Ory DS; Zheng W
    Assay Drug Dev Technol; 2017; 15(4):154-166. PubMed ID: 28631941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC3 Immunostaining in the Inferior Olivary Nuclei of Cats With Niemann-Pick Disease Type C1 Is Associated With Patterned Purkinje Cell Loss.
    Gurda BL; Bagel JH; Fisher SJ; Schultz ML; Lieberman AP; Hand P; Vite CH; Swain GP
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):229-245. PubMed ID: 29346563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium.
    Lloyd-Evans E; Morgan AJ; He X; Smith DA; Elliot-Smith E; Sillence DJ; Churchill GC; Schuchman EH; Galione A; Platt FM
    Nat Med; 2008 Nov; 14(11):1247-55. PubMed ID: 18953351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Specific iPSC-Derived Neural Differentiated and Hepatocyte-like Cells, Carrying the Compound Heterozygous Mutation p.V1023Sfs*15/p.G992R, Present the "Variant" Biochemical Phenotype of Niemann-Pick Type C1 Disease.
    Völkner C; Liedtke M; Untucht R; Hermann A; Frech MJ
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.
    Cougnoux A; Drummond RA; Collar AL; Iben JR; Salman A; Westgarth H; Wassif CA; Cawley NX; Farhat NY; Ozato K; Lionakis MS; Porter FD
    Hum Mol Genet; 2018 Jun; 27(12):2076-2089. PubMed ID: 29617956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease.
    Davidson J; Molitor E; Moores S; Gale SE; Subramanian K; Jiang X; Sidhu R; Kell P; Zhang J; Fujiwara H; Davidson C; Helquist P; Melancon BJ; Grigalunas M; Liu G; Salahi F; Wiest O; Xu X; Porter FD; Pipalia NH; Cruz DL; Holson EB; Schaffer JE; Walkley SU; Maxfield FR; Ory DS
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1545-1561. PubMed ID: 31051283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Cyclodextrin-threaded biocleavable polyrotaxanes ameliorate impaired autophagic flux in Niemann-Pick type C disease.
    Tamura A; Yui N
    J Biol Chem; 2015 Apr; 290(15):9442-54. PubMed ID: 25713067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease.
    Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Vite CH; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Bodamer O; Wang RY; Plummer E; Schaffer JE; Ory DS; Jiang X
    Mol Genet Metab; 2020 Apr; 129(4):292-302. PubMed ID: 32033912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker.
    te Vruchte D; Speak AO; Wallom KL; Al Eisa N; Smith DA; Hendriksz CJ; Simmons L; Lachmann RH; Cousins A; Hartung R; Mengel E; Runz H; Beck M; Amraoui Y; Imrie J; Jacklin E; Riddick K; Yanjanin NM; Wassif CA; Rolfs A; Rimmele F; Wright N; Taylor C; Ramaswami U; Cox TM; Hastings C; Jiang X; Sidhu R; Ory DS; Arias B; Jeyakumar M; Sillence DJ; Wraith JE; Porter FD; Cortina-Borja M; Platt FM
    J Clin Invest; 2014 Mar; 124(3):1320-8. PubMed ID: 24487591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1.
    Rodriguez-Gil JL; Watkins-Chow DE; Baxter LL; Elliot G; Harper UL; Wincovitch SM; Wedel JC; Incao AA; Huebecker M; Boehm FJ; Garver WS; Porter FD; Broman KW; Platt FM; Pavan WJ
    Dis Model Mech; 2020 Mar; 13(3):. PubMed ID: 31996359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic expression analyses reveal lysosomal, innate immunity proteins, as disease correlates in murine models of a lysosomal storage disorder.
    Alam MS; Getz M; Safeukui I; Yi S; Tamez P; Shin J; Velázquez P; Haldar K
    PLoS One; 2012; 7(10):e48273. PubMed ID: 23094108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.